Atopic Dermatitis is one of the most commonly seen conditions in the South Asian region, mainly comprising of countries such as India, China, Indonesia, Malaysia, etc. Therefore, the Asia Pacific market of atopic dermatitis drugs, according to the forecast is the fastest growing market with a CAGR of 7.57% between 2019-2027. The incidence and severity of atopic dermatitis differ based on environmental and dietary factors specific to the region.

ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

Asia Pacific Atopic Dermatitis Drugs Market by Route of Administration (Roa) (Topical, Oral, Injectable) by Drug Class (Topical Antibiotics, Topical Antihistamines, Topical Corticosteroids, Topical Moisturizers/emollients, Topical Calcineurin Inhibitors, Immunomodulators, Off-label Therapies, Systemic Agents, Pde-4 Inhibitor, Interleukin Inhibitor) by Geography.

Request free sample

Atopic Dermatitis is one of the most commonly seen conditions in the South Asian region, mainly comprising of countries such as India, China, Indonesia, Malaysia, etc. Therefore, the Asia Pacific market of atopic dermatitis drugs, according to the forecast is the fastest growing market with a CAGR of 7.57% between 2019-2027.

The incidence and severity of atopic dermatitis differ based on environmental and dietary factors specific to the region. The lack of awareness among patients is one of the major challenges faced by vendors in the Asia Pacific region. In the region, the symptoms start to show by the age of five and take a serious toll on the patient by the age of fifteen. Lack of awareness causes delays in treatment, which increases the severity of atopic dermatitis in adulthood. Atopic dermatitis is highly prevalent in the Asia Pacific, with a large unmet need for satisfactory medications compared to other regions. In India alone, 20-30% of the population suffers from at least one allergic disease.

The leading brands of existing atopic dermatitis drugs market are Bayer Ag, Allergan Plc, Aqua Pharmaceuticals (An Almirall Company), Bayer Ag, Stiefel Laboratories, Inc, Bristol-Myers Squibb, Astellas Pharma Inc., Biofrontera Ag, Galderma Sa, Leo Pharma, Bristol-Myers Squibb, Stiefel Laboratories Inc, Pfizer, Sanofi Sa, Novartis Ag, Encore Dermatology, Regeneron Pharmaceuticals, Valent Pharmaceutical Inc., Meda Pharmaceuticals (Mylan N.V.).

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
        • INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
    1. MARKET DETERMINANTS
      • MARKET DRIVERS
        • GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
        • GROWING FOCUS ON SYSTEMATIC THERAPIES
        • INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
      • MARKET RESTRAINTS
        • STRINGENT REGULATIONS FOR PRODUCT APPROVAL
        • GENERIC COMPETITION
      • MARKET OPPORTUNITIES
        • INCREASING M&A LEADING TO MARKET CONSOLIDATION
        • LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
        • GROWING FOCUS ON NOVEL DRUGS
      • MARKET CHALLENGES
        • BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
        • HIGHLY GENERICIZED MARKET
        • POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE
    1. MARKET SEGMENTATION
      • MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
        • TOPICAL
        • ORAL
        • INJECTIBLES
      • MARKET BY DRUG CLASS 2019-2027
        • TOPICAL ANTIBIOTICS
        • TOPICAL ANTIHISTAMINES
        • TOPICAL CORTICOSTEROIDS
        • TOPICAL MOISTURIZERS/EMOLLIENTS
        • TOPICAL CALCINEURIN INHIBITORS
        • IMMUNOMODULATORS
        • OFF-LABEL THERAPIES
        • SYSTEMIC AGENTS
        • PDE4 INHIBITOR
        • INTERLEUKIN INHIBITOR
    1. KEY ANALYTICS
      • PORTER’S FIVE FORCES ANALYSIS
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • PIPELINE ANALYSIS
      • LEGAL, POLICY AND REGULATORY ISSUES
    2. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • INDIA
        • CHINA
        • JAPAN
        • AUSTRALIA AND NEW ZEALAND
        • SOUTH KOREA
        • REST OF ASIA PACIFIC
    1. COMPANY PROFILES
      • ALLERGAN PLC
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • ASTELLAS PHARMA INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BAYER AG
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • BIOFRONTERA AG
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • BRISTOL-MYERS SQUIBB
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • STIEFEL LABORATORIES, INC
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
      • ENCORE DERMATOLOGY
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • GALDERMA SA
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • LEO PHARMA
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • MEDA PHARMACEUTICALS (MYLAN N.V.)
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • NOVARTIS AG
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • PFIZER
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • REGENERON PHARMACEUTICALS
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • SANOFI SA
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS
        • STRATEGIC INITIATIVES
      • VALENT PHARMACEUTICAL INC.
        • COMPANY OVERVIEW
        • PRODUCT PORTFOLIO
        • SWOT ANALYSIS

     

    TABLE LIST

    TABLE  1      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    TABLE  2      RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET

    TABLE  3      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)

    TABLE  4      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)

    TABLE  5      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN ORAL  ROA 2019-2027 ($ MILLION)

    TABLE  6      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)

    TABLE  7      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

    TABLE  8      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)

    TABLE  9      ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)

    TABLE  10    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)

    TABLE  11    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)

    TABLE  12    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)

    TABLE  13    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)

    TABLE  14    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)

    TABLE  15    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)

    TABLE  16    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)

    TABLE  17    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)

    TABLE  18    PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET

    TABLE  19    REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET

    TABLE  20    ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

     

    FIGURE LIST

    FIGURE  1    ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  2    INDIA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  3    CHINA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  4    JAPAN ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  5    AUSTRALIA AND NEW ZEALAND ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  6    SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE  7    REST OF ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • INDIA
        • CHINA
        • JAPAN
        • AUSTRALIA AND NEW ZEALAND
        • SOUTH KOREA
        • REST OF ASIA PACIFIC
    1. MARKET SEGMENTATION
      • MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
        • TOPICAL
        • ORAL
        • INJECTIBLES
      • MARKET BY DRUG CLASS 2019-2027
        • TOPICAL ANTIBIOTICS
        • TOPICAL ANTIHISTAMINES
        • TOPICAL CORTICOSTEROIDS
        • TOPICAL MOISTURIZERS/EMOLLIENTS
        • TOPICAL CALCINEURIN INHIBITORS
        • IMMUNOMODULATORS
        • OFF-LABEL THERAPIES
        • SYSTEMIC AGENTS
        • PDE4 INHIBITOR
        • INTERLEUKIN INHIBITOR

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type